The authors comment that combination antiretroviral therapy, despite the well-characterised drug–drug interactions, does not appear to affect the safety of dose-adjusted statins. They do however highlight that simvastatin, despite proving to be safe and effective, should not be prescribed concomitantly with protease inhibitors due to pharmacokinetic interactions.